Kornimate/medical-research-clean huggingface dataset:
qol and mental health using apd with remote monitoring system

Conditions: Quality of Life; Mental Health Wellness 1

Summary: although peritoneal dialysis (pd) is a representative renal replacement therapy along with hemodialysis, number of pd patients decreases every year. among the various contributing factors for such trends, the essential issue that the patients should perform dialytic therapy by themselves is thought to be critical for the patients to avoid choosing pd as primary dialytic therapy. in particular, unlike hemodialysis, the patients with pd have troubles in getting timely medical advice in their daily life, although continuous advice are essential for maintaining therapy. thus, remote monitoring and control system is believed to be useful in pd therapy. automated pd (apd) is a good option because of its convenience and improved accessibility. so, in korea, although the rate of incident pd patients was decreased, the proportion of apd were rapidly increased (3.7% in 2001 vs. 39% in 2018, korean society of nephrology (ksn) data) in the covid-19 pandemic, the investigators should improve remote therapy monitoring (rtm). technologies that collect medical information and transmit it to health care providers for patient management, have the potential to improve the patients' outcomes without visiting hospital receiving automated peritoneal dialysis (apd) at home. however, there are only a few retrospective studies and no prospective study about remote patients monitoring programs in apd. remote medical service is currently illegal in south korea. however, recently the korean government has approved remote medical service in only a few areas of gangwon province, including wonju city, which belongs to our institution. thus, the investigators aim to use such a benefit to investigate the 'quality of life (qol)' in korean patients undergoing apd. the investigators plan to compare the various clinical indexes, including mainly qol, mental health focusing depression, and volume-nutritional status between the patients with previous classic apd and apd combined by the sharesourcetm system (baxter co.).


Eligibility criteria:
inclusion criteria: * more than 18 years old * esrd patients on apd(≥1 month) * consent to participate in the study exclusion criteria: * patients who plan to receive kidney transplantation within 1 year * patients with co-morbidities: cardiovascular disease(myocardial infarction, heart failure, arrhythmia), cancer, psychiatric diseases, liver cirrhosis

Keywords: remote control automated peritoneal dialysis
recombinant human lactoferrin administered orally for the prevention of antibiotic associated diarrhea in adult patients

Conditions: Diarrhea

Summary: the purpose of the study is to evaluate the efficacy and safety of recombinant human lactoferrin administered orally for the prevention of antibiotic associated diarrhea in adult patients.


Eligibility criteria:
inclusion criteria: * all patients must meet all of the inclusion criteria listed below at the time of enrollment. 1. male and female patients 50 years of age and older. 2. resident of a participating long term care facility. 3. able to consume 30 ml of liquid solution two time per day by mouth or enteral feeding tube. 4. patient has had no antibiotics in the 4 weeks preceding enrollment in the study. 5. patient has been started on a broad spectrum antibiotic(s) for an infection other than gastroenteritis. 6. patient has a life expectancy greater than 6 months. 7. patient or health care agent is able and willing to sign a written informed consent. 8. patient or caregiver is able and willing to complete diary of daily bowel movement information (number, formed or unformed, time) during any portion of the 8 week study. exclusion criteria: 1. patient has an ileostomy. 2. patient has a prior history of major gastrointestinal surgery such as partial small bowel or colon resection or gastric bypass. 3. patient has a history of inflammatory bowel disease. 4. patient has a history of chronic diarrhea associated with irritable bowel syndrome or other etiologies. 5. patient has a history of severe constipation requiring use of enemas or disimpaction within 30 days prior to enrollment. 6. patient has signs or symptoms of c. difficile infection including diarrhea. 7. patient has signs or symptoms of acute or chronic diarrhea. 8. patient has known sensitivity or allergy to rice or rice products. 9. patient has significant medical problems which in the judgment of the principal investigator or medical monitor may interfere with participation in the study. 10. patient is not receiving an antibiotic regimen consisting of a broad spectrum antibiotic. 11. patient has participated in an investigational study using an investigational product within 30 days of randomization.

Keywords: antibiotic associated diarrhea in adult patients
cmr in myocardial infarction with nonobstructive coronary arteries

Conditions: Cardiac Magnetic Resonance; Myocardial Infarction with Nonobstructive Coronary Arteries; Strain; Extracellular Volume

Summary: minoca is accompanied by a worse prognosis, which is related to the inability to clarify the etiology.cmr has been explicitly recommended by guidelines as an etiologic diagnostic tool for minoca. although cmr-related parameters, such as strain and ecv, have been shown to be associated with prognosis in patients with myocardial infarction. however, the relationship between cmr-strain or ecv and minoca is unclear. the aim of this study was to investigate the characterization of cmr-strain or ecv in patients with minoca and the relationship with prognosis.


Eligibility criteria:
inclusion criteria: 1. complete cmr during hospitalization; 2. cag results suggesting coronary stenosis of less than 50%; 3. peak hstnt above the 99th percentile. exclusion criteria: * cmr image sequences are missing or of poor quality.
immune reconstitution to cmv after hsct: impact of clinical factors and therapy strategies

Conditions: CMV Infection; Hematopoietic Stem Cell Transplantation

Summary: cytomegalovirus (cmv) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (hsct). the course and outcome of cmv infection are different clinically, and the mechanism of cmv infection after transplantation has not been clarified. reconstitution of cellular immunity after hsct is a critical determinant of the control of cmv infection. investigators will dynamically monitor the cmv-specific cellular immune reconstitution after hsct，and analyze the clinical factors and therapy strategies affecting recovery of cmv-specific immunity during 1 year after hsct.

cytomegalovirus (cmv) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (hsct). the course and outcome of cmv infection are different clinically, and the mechanism of cmv infection after transplantation has not been clarified. reconstitution of cellular immunity after hsct is a critical determinant of the control of cmv infection. investigators will collect peripheral blood at 1 month, 2 month, 3 month, and 6 month after hsct from the participated patients, and dynamically monitor the cmv-specific t and nk cellular immune reconstitution. investigators will also analyze the clinical factors and therapy strategies affecting recovery of cmv-specific immunity during 1 year after hsct.

Eligibility criteria:
inclusion criteria: * be receiving a first allogeneic hsct. * is male or female, from 14 years to any years of age inclusive. * the participant (or legally acceptable representative) agree for cellular immune investigation and has provided documented informed consent/assent for the study. exclusion criteria: * received a previous allogeneic hsct (note: receipt of a previous autologous hsct is acceptable). * has a history of cmv end-organ disease within 6 months prior to allocation. * has severe organ (hepatic , renal, cardical) insufficiency within 5 days prior to allocation. * any rapidly-progressing disease or immediately life-threatening illness.
a phase 3 study to evaluate the efficacy and safety of tralokinumab in adults and adolescents with uncontrolled asthma

Conditions: Uncontrolled Asthma

Summary: a 52-week, multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of tralokinumab in adults and adolescents with asthma inadequately controlled on inhaled corticosteroid plus long-acting β2-agonist

this is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting β2-agonist and having a history of asthma exacerbations. approximately 770 subjects will be randomized globally. subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period.

Eligibility criteria:
inclusion criteria: 1. age 12 -75 2. documented physician-diagnosed asthma. 3. documented treatment with ics at a total daily dose corresponding to ≥500μg fluticasone propionate dry powder formulation equivalents) and a laba 4. morning pre-bd fev1 value of ≥40 and \<80% value (\<90% for patients 12 to 17 years of age) of their pnv. 5. post-bd reversibility of ≥12% and ≥200 ml in fev1 6. acq-6 score ≥1.5 exclusion criteria: 1. pulmonary disease other than asthma 2. history of anaphylaxis following any biologic therapy 3. hepatitis b, c or hiv 4. pregnant or breastfeeding 5. history of cancer 6. current tobacco smoking or a history of tobacco smoking for ≥ 10 pack-years 7. previous receipt of tralokinumab
observational study of the analgesic effect of treatment with rtms in patients with chronic neuropathic pain

Conditions: Chronic Pain

Summary: for ten years, rtms, repetitive transcranial magnetic stimulation of the motor cortex, has found its place in the treatment of drug-resistant neuropathic pain. patients relieved by some sessions may thereafter receive a chronic invasive stimulation via electrodes implanted through a neurosurgical procedure. this is common practice at the university hospital of caen and in different chu with the proper equipment rtms. it seems permissible to provide in our center only a non-invasive technique for patients challenged with brain surgery, since according to the various meta-analyzes the analgesic efficacy of rtms seems to be correlated to the repetition of sessions. assessment centers and the treatment of pain allow a multidimensional assessment, bio-psycho-social of patients in order to optimize their management and experience efficiently analgesics first- and second-line. we propose a study evaluating the analgesic efficacy of rtms, in relevant stimulation parameters reproduced according to a literature review, during 3 months after 5 active sessions separated by one week apart, in 15 patients with neuropathic pain chronic refractory to treatment of first and second line, followed by multidisciplinary center specializing in chronic pain lower normandy. the quality of life will also be assessed by validated scales, and the results will be compared to the literature data.


Eligibility criteria:
inclusion criteria: * patient 18 to 70 years with: 1. pain lasting for more than six months; 2. monitoring in cetd in normandy; 3. having had a bio-psycho-social assessment and have been the subject of a multidisciplinary discussions recorded in the medical record; 4. presenting unilateral neuropathic pain, central or peripheral origin: * may affect the face, * upper limb, * or hémicorps but including at least the upper limb; 5. with neuropathic pain screening test positive (≥ dn4 4/10); 6. etiology objectified by further examinations (mri, scanner, or emg, pes mep); 7. resistant to usual treatments: less than 50% improvement compared to the initial pain (en or eva) in patients who received an effective dose for treatment of first and a second intention. exclusion criteria: * contraindications of rtms: 1. brain implanted ferromagnetic material, 2. implanted neurostimulator (cortical and deep brain, spinal cord) 3. cochlear implants 4. active epilepsy (seizures despite existence of a current treatment) 5. pacemakers 6. hearing loss or current taking ototoxic drugs (aminoglycosides, cisplatin) * pregnancy, breastfeeding, lack of effective contraception for patients of childbearing age * psychiatric illness decompensated * cancer pain and post-chemotherapy * severe cognitive disorders
effect of a probiotic strain lactobacillus paracasei k56 on metabolic symptom - a pilot study

Conditions: Obesity; Adiposity

Summary: recent data suggest that gut microbiota can function as an environmental factor that modulates the amount of body fat and obese individuals have an altered gut microbiota.the results of previous animal studies have suggest that a probiotic strain lactobacillus paracasei k56 have reduced high-fat diet induced obesity. in this before-after pilot study, the participants were randomly assigned to 8 groups to compare the fat-reducing effect of the lactobacillus paracasei k56 by continuously supplementing different product prototypes , and screen the best probiotic k56 prototype with the effect of fat reduction.


Eligibility criteria:
inclusion criteria: * bmi\>=30kg/m2,or percent of body fat(pbf) \>=25% for male, \>=30 for female. * age: 18 - 60 years old adults exclusion criteria: * patients with severe chronic diseases (coronary heart disease, diabetes, hypertension, immune deficiency, mental disorders, tumors, liver and kidney dysfunction, etc.) and complications;irritable bowel syndrome * history of intervention with fat-reducing drugs or health products in the past 2 months * take weight control measures (diet, exercise, etc.) within the past month * those who cannot guarantee to maintain their current lifestyle during the trial period * those who fail to consume the tested samples as required, or fail to follow up on time, resulting in failure to determine the efficacy

Keywords: obesity lactobacillus paracasei body fat visceral fat area
effect of the consumption of a combination of plant extracts (bsl_ep026) on serum uric acid.

Conditions: Hyperuricemia

Summary: the objective of this study is to evaluate the effect of the combination of a combination of plant extracts (bsl_ep026) on blood and urine uricemia levels in individuals with levels at the limit of the values considered normal or moderately high.

hyperuricemia is an abnormally high level of uric acid in the blood, resulted because of an increased production of uric acid, decreased excretion of uric acid, or both. this can cause gout and nephrolithiasis, and it has also been related to metabolic syndrome, diabetes mellitus, cardiovascular disease and chronic kidney disease. some plant extracts have diuretic activity that could contribute to improve uric acid excretion. this effect would lead to a decrease in uric acid plasma levels and, secondarily, to an action on its metabolic pathway of endogenous biogeneration. on the other hand, uric acid has a double reabsorption-elimination step in the renal tubules and the flavonoids of both extracts impede the processes of renal resorption promoting urinary elimination, in addition to increase the ph of the urine (higher than ph 5.8), which favors the non-precipitation or formation of urate stones. finally, the routine (present in the used extracts) inhibit the uric acid formation pathway from purines, which would act synergistically. in this project, the effect of the intake of a combination plant extracts on uricemia levels will be studied.

Eligibility criteria:
inclusion criteria: * blood uric acid levels greater than 7 mg/dl in men and 6 mg dl in women. * accept freely to participate in the study and sign the informed consent document. exclusion criteria: * having treatment that can affect uric acid levels. * use of diuretics. * follow a low purine diet. * take a food supplement or drug that interferes with uric acid metabolism and renal system function. * have an allergy to birch and/or orthosiphon or another component of the test products. * low compliance expectation.

Keywords: hyperuricemia plant extracts
genetic variants and perioperative morbidity and mortality

Conditions: Anesthesia; Analgesia; Surgical Procedure, Operative

Summary: prospective association study to analyse perioperative patients' outcome. outcome comprises intraoperative and postoperative complications e.g. cardio-vascular events, allergic reactions, possible variables which might have on influence: patient- and surgery-related data, patients' genetic background etc.

background anesthesia and surgery are related to unwanted adverse events, side effects and postoperative discomfort. whereas severe complications like cardiovascular events are rare, postoperative side effects like nausea and vomiting, pain, long-lasting pain and pain related interference of daily activities are frequent. the question arises which patient is at specific risk for this sequelae. pre-exiting predisposing factors (e.g. patients' genetic background), surgery and anesthesia related variables (drugs, techniques administered for anesthesia and analgesia) as well as psychological and social factors might influence the outcome. in this prospective association study these variables will be investigated in a well-described patient cohort presenting for elective surgery. objective the aim of this study is to associate perioperative and postoperative complications and side effects as well as long-term outcome after surgery to patient- and surgery-related variables, including genetic variants. methods prospective association study performed in two independent patient cohorts.

Eligibility criteria:
inclusion criteria: * 18 years and older * written informed consent * scheduled surgery exclusion criteria * no informed consent * cognitive impairment

Keywords: anesthesia recovery period postoperative complications pain pain measurement postoperative nausea and vomiting quality of life genetic association study
dexmedetomidine on post-operative blood pressure in bain arteriovenous malformation embolization

Conditions: Anesthesia

Summary: aim of this trial is to study the effect of dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization. the patients were randomized allocated to either dexmedetomidine group or control group. patients in dexmedetomidine group will receive intravenous dexmedetomidine while the control group will receive normal saline. post-operative anti-hypertensive drug, visual analogue score,post-operative analgesics consumption, quality of recovery score, ramsay score, and adverse events were recorded.

aim of this trial is to study the effect of dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization. the patients were randomized allocated to either dexmedetomidine group or control group according to a random number. patients in dexmedetomidine group will receive intravenous dexmedetomidine while the control group will receive normal saline. post-operative anti-hypertensive drug, visual analogue score,post-operative analgesics consumption, quality of recovery score-15 items, ramsay score, and adverse events were recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing brain arteriovenous malformation embolization in the fist affiliated hospital, sun yat-sen university, aged 18-65 years, available to chat with,and the tracheal tube was extubated after surgery immediately. exclusion criteria: * abuse anesthetic analgesics and sedative drugs, or allergic to dexmedetomidine or other anesthetics, hypotension or bradycardia before surgery, severe pulmonary disease with saturation of pulse oximetry less than 90% before surgery, or patients refused to attend in this study.

Keywords: dexmedetomidine brain arteriovenous malformation embolization post-operative hypertension
palliative treatments for patients with advanced hepatocellular carcinoma (hcc)

Conditions: Hepatectomy; Hepatocellular Carcinoma; Sorafenib

Summary: the standard treatment choice for advanced hepatocellular carcinoma (hcc) is sorafenib, and its efficacy is limited. more active treatments were performed in patients with advanced hcc in china, which include radical hepatectomy or tace. the study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.

this is a prospective non-randomized controlled study. patients with advanced hepatocellular carcinoma (bclc c stage) who underwent palliative resection or tace followed with sorafenib or treated by sorafenib alone will be included. the patients will be divided to group a (palliative resection plus sorafenib), group b (palliative tace plus sorafenib), and group c (sorafenib alone). the sample size will be about 200 cases altogether.

Eligibility criteria:
inclusion criteria: * male or female patients \> 18 years of age. * diagnosed to have advanced hcc (bclc c stage). * patients who have a life expectancy of at least 12 weeks. * patients whose primary tumor can be resected. definition of resectable in this study: * tumor number \<=2. * if number of tumors \>= 3, then all tumors were located in the same lobe. * without tumor invasion of the main trunk of the portal vein, or hepatic duct, or caval vein. * hepatocellular carcinoma with histological diagnose or clinical diagnose according to aasld. * no major post-operative complication. * patients who have an ecog ps of 0, or 1. * cirrhotic status of child-pugh class a only. * the following laboratory parameters: platelet count \> 60 x 109/l hemoglobin \> 8.5 g/dl albumin \> 3.5 g/dl total bilirubin \< 25μmol/l alanine transaminase (alt) and ast \< 2.5 x upper limit of normal serum creatinine \<1.5 x the upper limit of normal prothrombin time (pt)\<3 seconds above control. • patients who give written informed consent. exclusion criteria: * previous or concurrent cancer that is distinct in primary site or histology from hcc. * history of cardiac disease. * active clinically serious infections (\> grade 2 national cancer institute \[nci\]-common terminology criteria for adverse events \[ctcae\] version 3.0) * known history of human immunodeficiency virus (hiv) infection * known central nervous system tumors including metastatic brain disease. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * history of organ allograft. * known or suspected allergy to the investigational agent or any agent given in association with this trial. * pregnant or breast-feeding patients. * any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study. * excluded therapies and medications, previous and concomitant: systemic chemotherapy and target drug other than sorafenib. antiviral treatment is allowed. * radiotherapy except for which done for bone metastases palliatively.

Keywords: hepatocellular carcinoma, treatments, survival